MDS-128: Azacitidine and Venetoclax Combination for Upfront Treatment of Higher-Risk Myelodysplastic Syndromes
| Autor: | Rami S. Komrokji, David A. Sallman, Kendra Sweet, Najla Al Ali, Andrew T. Kuykendall, Onyee Chan, Jeffrey E. Lancet, Eric Padron |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Venetoclax business.industry Myelodysplastic syndromes Azacitidine Context (language use) Hematology medicine.disease stomatognathic diseases chemistry.chemical_compound chemistry Internal medicine Ven Overall survival medicine heterocyclic compounds Disease characteristics business neoplasms Complete response medicine.drug |
| Zdroj: | Clinical Lymphoma Myeloma and Leukemia. 21:S341 |
| ISSN: | 2152-2650 |
| Popis: | Context: Azacitidine (aza) remains the backbone of treating higher-risk MDS patients (pts), with less than 20% of pts achieving complete response (CR) and median overall survival of 14–18 months. Ongoing studies in higher-risk MDS are assessing the role of adding venetoclax (ven) to aza in higher-risk MDS. Objective: We report, here, single-institution experience of aza/ven combination in the upfront treatment of higher-risk MDS, comparing it to historical aza alone. Design: We identified 35 pts who received aza/ven for intermediate or higher-risk MDS by R-IPSS compared to 1175 similar-risk MDS pts who historically received aza upfront therapy alone. Results: The median follow-up for the aza/ven group was 15 months (mo) compared to 93 mo for aza alone. No differences were observed in baseline demographic or disease characteristics comparing aza/ven group to aza alone except for higher rates of ASXL-1 and N-RAS somatic mutations (SM) among aza/ven treated pts. There was no difference in median OS among the two groups: median OS was 20 mo for both groups. The CR/marrow CR (mCR) rate was higher with the aza/ven combination, 71% (31%/40%), compared to 25% for aza alone (13%/12%) (p Conclusion: Aza/ven combination is associated with higher responses overall and among ASXL-1 SM higher-risk MDS pts and encouraging early data support aza/ven as a bridge to AHSCT, with 90% 2-year OS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect